We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byVeronica Wayt
Modified about 1 year ago
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia by Francesco Buccisano, Luca Maurillo, Alessandra Spagnoli, Maria Ilaria Del Principe, Daniela Fraboni, Paola Panetta, Tiziana Ottone, Maria Irno Consalvo, Serena Lavorgna, Pietro Bulian, Emanuele Ammatuna, Daniela F. Angelini, Adamo Diamantini, Selenia Campagna, Licia Ottaviani, Chiara Sarlo, Valter Gattei, Giovanni Del Poeta, William Arcese, Sergio Amadori, Francesco Lo Coco, and Adriano Venditti Blood Volume 116(13): September 30, 2010 ©2010 by American Society of Hematology
Clinical outcome in different cytogenetic groups according to MRD status after consolidation. Francesco Buccisano et al. Blood 2010;116: ©2010 by American Society of Hematology
Assessment of MRD at the end of consolidation splits FLT3 wild-type in 2 categories with different prognoses. Francesco Buccisano et al. Blood 2010;116: ©2010 by American Society of Hematology
AML risk stratification may be simplified integrating determination of MRD at the end of consolidation, with conventional cytogenetic/genetic classification. Francesco Buccisano et al. Blood 2010;116: ©2010 by American Society of Hematology
Emerging JAK Inhibitors in Myelofibrosis: Determining the Right Agent for the Right Patient.(Madrid) How to use prognosis assessment criteria for MF management.
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men by Bas de Laat, Philip G. de Groot, Ronald H.
STATUS OF DETECTION OF MINIMAL RESIDUAL DISEASE (MRD) IN ACUTE LYMPHOBLASTIC LEUKEMIAS DEPT OF MOL ONCOLOGY CANCER INSTITUTE (WIA) ADYAR, CHENNAI
The WHO Classification of Hematological Malignancies Pathology Grand Rounds April
Molecular Haemato-Oncology at Bristol Genetics Laboratory Kayleigh Templeman
Leukemia The leukemias are the most common malignant neoplasms in childhood: – 41% of all malignancies that occur in children less than 15 yrs. 77% - Acute.
Dr A. ASSAL French Blood Services (EFS) PARIS. FRANCE Second WHO consultation January 27 & 28 January, 2009 Standardization of PCR for Trypanosoma cruzi.
What is MDS MDS comprises a heterogeneous group of clonal haematopoietic stem cell malignancies characterised by 1,2 –BM dysplasia hypercellular BM is.
Observational study to determine the rate of occurrence of invasive mould disease and treatment outcomes in at-risk patients: a European prospective invasive.
The Reliable Life Defense. Each vial contains: Each vial contains: Recombinant human granulocyte colony-stimulating factor (G-CSF) 300 µg in a volume.
Risk factor definitions 02 RISK FACTOR Something that increases the chances of getting a disease Intrinsic risk factor …is an integral part of the individual.
Changes for PY 2005 Changes to NRS Reporting PY 2005 American Institutes for Research February 2005.
Dr. Amal S. Ahmed Ass Prof.Clinical Pathology Suez Canal University.
Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.
Barriers to Participation in Clinical Trials Pediatric Oncology.
COMPLEMENTARY AND ALTERNATIVE MEDICINE AND SPINAL CORD INJURY Dr. Steve Williams, MD Naomi Goodman, MPH Dr. Kristin Gustafson, DO Dr. Feng Wang, MD, MPH.
Acute Lymphoblastic Leukemia An Overview Aziza Shad, MD.
“Molecular Pathology past present & future” Thomas Kerr Principal Healthcare Scientist Molecular Pathology Pathology Department Southern General Hospital.
Acute lymphoblastic leukemia in adults. ALL. Incidence.
Combining neuropsychology and genetics in the study of mood disorders Daniel Smith MRCPsych Division of Psychiatry, University of Edinburgh Specialist.
Non-Hodgkin’s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department.
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL by Arian.
Severe coagulopathy Specific genetic Specific genetic lesion lesion Response to differentiating agents (RA, ATO) agents (RA, ATO) Striking sensitivity.
Diagnostic Work-Up Imaging: – X-Ray – MRI – UTZ. Cervical Spine Radiograph Alignment is satisfactory Vertebral height is preserved Minimal osteophytes.
Using Wireless Technology and the Internet to Improve Patient Outcomes.
When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1.
1 Chapter 38 Inherited and Neurodegenerative Diseases Copyright © 2012, American Society for Neurochemistry. Published by Elsevier Inc. All rights reserved.
Consolidated User Story 1: Chronic Diseases (cancer, occupational health) Chronic Diseases, Outpatient Flow Patient, Provider/Physician, Laboratory, PH.
Data Mining in Genomics: the dawn of personalized medicine Gregory Piatetsky-Shapiro KDnuggets Connecticut College, October.
© 2016 SlidePlayer.com Inc. All rights reserved.